🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Colorado
Clinical trial register · United States · industry-sponsored

Clinical Trials in Colorado

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9110 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:16 UTC
9110
Studies in scope
industry-sponsored, all four open statuses
4947
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 110 Florida 92 Colorado 69 Georgia 67 Illinois 57
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca88 Janssen Research & Development, LLC69 Eli Lilly and Company65 Merck Sharp & Dohme LLC64 Novartis Pharmaceuticals55 Clear sponsor filter
State
California110 Florida92 Colorado69 Georgia67 Illinois57
All 42 states
Target enrolment
to
69 of 9110 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
NCT07309445Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Observational
150
Alabama, Arkansas, California, Colorado, Florida, Illinois, Indiana, Michigan
2026-06-12
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
644
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
Janssen Research & Development, LLC
Phase 3
460
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Michigan, New York
2026-05-22
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
Janssen Research & Development, LLC
Phase 3
530
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-04-21
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441Multiple Myeloma
Janssen Research & Development, LLC
Phase 2
157
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2026-02-08
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-04
Recruiting
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
NCT07217587Myasthenia Gravis
Janssen Research & Development, LLC
Phase 3
115
California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Michigan
2026-01-05
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-12-19
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
882
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-09-10
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
1,203
California, Colorado, Connecticut, District of Columbia, Florida, Iowa, Louisiana, Maryland
2025-09-02
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
Phase 3
600
Alabama, Arizona, Arkansas, California, Colorado, Delaware, Florida, Illinois
2025-06-04
Recruiting
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
NCT06533098Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC
Phase 3
50
Alabama, California, Colorado, Illinois, Indiana, Iowa, New York, North Carolina
2025-02-10
Recruiting
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
NCT06800313Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2
190
Colorado, Connecticut, Florida, Louisiana, Massachusetts, Michigan, Nebraska, New York
2025-02-06
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 2
480
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-12-16
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
700
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2024-12-12
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
Janssen Research & Development, LLC
Phase 3
655
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Michigan
2024-12-04
Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
NCT06768489Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
240
Colorado, Georgia
2024-12-04
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2024-10-18
Recruiting
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms
Janssen Research & Development, LLC
Phase 1
260
Arizona, Colorado, Florida, Indiana, Michigan, Washington
2024-10-15
Recruiting
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
NCT06500884Multiple Myeloma
Janssen Research & Development, LLC
Phase 2
210
California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington
2024-08-26
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306Depressive Disorder, Major
Janssen Research & Development, LLC
Phase 3
752
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-07-25
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
108
Arizona, Colorado, Florida, Georgia, Indiana, Ohio, Texas
2024-06-07
Active, closed
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
Janssen Research & Development, LLC
Phase 2
333
California, Colorado, Florida, Idaho, Illinois, Iowa, Minnesota, Missouri
2024-05-30
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 1/2
287
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Missouri
2024-04-22
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
641
Arkansas, California, Colorado, Florida, Illinois, Indiana, Kansas, Louisiana
2024-04-18
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
272
Arkansas, California, Colorado, Florida, Illinois, Indiana, Kansas, Michigan
2024-04-09
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
Janssen Research & Development, LLC
Phase 1
300
California, Colorado, Florida, Georgia, Michigan, New Jersey, New York, North Carolina
2023-12-20
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Phase 3
120
California, Colorado, Florida, Illinois, Indiana, Kentucky, Maryland, Massachusetts
2023-12-20
Recruiting
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
NCT06095089Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
355
Colorado, Georgia, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania
2023-11-01
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
Janssen Research & Development, LLC
Phase 3
420
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2023-08-31
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
Janssen Research & Development, LLC
Phase 3
20,284
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-04-11
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
614
Alaska, Arizona, California, Colorado, Connecticut, Florida, Iowa, Louisiana
2023-03-29
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
Janssen Research & Development, LLC
Phase 3
1,135
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2023-03-23
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
Janssen Research & Development, LLC
Phase 3
12,523
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-02-15
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1
180
California, Colorado, New York, North Carolina, Pennsylvania, Texas
2022-11-22
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LLC
Phase 2/3
201
Colorado, Florida, Georgia, Kansas, Maryland, Massachusetts, Michigan, Missouri
2022-09-23
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 2
577
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana
2022-09-19
Active, closed
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
418
Arizona, California, Colorado, Florida, Georgia, Kansas, Michigan, New York
2022-09-13
Active, closed
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC
Phase 1/2
166
California, Colorado, Iowa, Kentucky, New Jersey, North Carolina, Ohio, Pennsylvania
2022-08-12
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
Phase 3
418
California, Colorado, Florida, Kansas, Michigan, New Jersey, New York, Oregon
2022-08-05
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2022-07-22
Recruiting
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
NCT05265273Myasthenia Gravis
Janssen Research & Development, LLC
Phase 2/3
12
Arizona, California, Colorado, Florida, Kansas, Michigan, Pennsylvania
2022-07-20
Active, closed
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
NCT05338775Relapsed/ Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
74
Colorado, New York, North Carolina, Tennessee
2022-05-25
Active, closed
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
NCT05316155Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 1/2
235
Alabama, California, Colorado, Florida, Illinois, Indiana, Kentucky, Louisiana
2022-04-11
Active, closed
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049Crohn Disease
Janssen Research & Development, LLC
Phase 3
350
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-01-19
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
776
Alabama, Arizona, California, Colorado, Florida, Georgia, Mississippi, Nebraska
2021-11-17
Active, closed
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT05050097Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
166
Alabama, California, Colorado, Georgia, Indiana, New Jersey, New York, North Carolina
2021-09-22
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622Myasthenia Gravis
Janssen Research & Development, LLC
Phase 3
199
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts
2021-07-15
Active, closed
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT04722146Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
140
Alabama, California, Colorado, Georgia, Indiana, Missouri, New Jersey, New York
2021-03-12
Active, closed
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623Urinary Bladder Neoplasms
Janssen Research & Development, LLC
Phase 2
220
Arizona, California, Colorado, Illinois, Indiana, Kansas, Michigan, New York
2020-12-18
Active, closed
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426Multiple Myeloma
Janssen Research & Development, LLC
Phase 1/2
228
Alabama, Arkansas, Colorado, Georgia, Minnesota, Missouri, New York, North Carolina
2020-12-15
Active, closed
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862Urinary Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
518
California, Colorado, Florida, Georgia, Illinois, Michigan, Nebraska, New Jersey
2020-12-07
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
1,074
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2020-09-30
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
696
Alabama, Arizona, California, Colorado, Connecticut, Florida, Indiana, Louisiana
2020-09-23
Active, closed
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
419
Alabama, Arizona, California, Colorado, Connecticut, Florida, Iowa, Kansas
2020-06-12
Active, closed
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445Ulcerative Colitis
Janssen Research & Development, LLC
Phase 2/3
1,064
California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky, Massachusetts
2019-09-26
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Phase 2/3
118
California, Colorado, Florida, Illinois, Kansas, Louisiana, Michigan, Missouri
2019-08-15
Active, closed
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
2,517
California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana, Massachusetts
2019-06-11
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641Castration-Resistant Prostatic Cancer
Janssen Research & Development, LLC
Phase 3
765
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois
2019-01-25
Active, closed
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT03596645Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
84
California, Colorado, Connecticut, Delaware, Georgia, Minnesota, New York, Tennessee
2018-10-29
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
Janssen Research & Development, LLC
Phase 2/3
1,409
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2018-04-13
Active, closed
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
NCT03473743Urothelial Carcinoma
Janssen Research & Development, LLC
Phase 1/2
125
Colorado, Kentucky, Maryland, New Jersey, New York, North Carolina, Ohio, Pennsylvania
2018-04-05
Active, closed
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Phase 2
136
Arizona, Colorado, Florida, Indiana, Maryland, Michigan, New York, Pennsylvania
2018-03-02
Active, closed
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03399799Hematological Malignancies
Janssen Research & Development, LLC
Phase 1
279
Alabama, California, Colorado, New York, Tennessee
2017-12-16
Active, closed
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
NCT03145181Hematological Malignancies
Janssen Research & Development, LLC
Phase 1
302
California, Colorado, New York, North Carolina, Pennsylvania
2017-05-16
Active, closed
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
NCT02365597Urothelial Cancer
Janssen Research & Development, LLC
Phase 2
239
Arizona, California, Colorado, District of Columbia, Illinois, Iowa, Kentucky, Minnesota
2015-04-22
Rows per page Showing 1–69 of 69
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-usa/state/colorado

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.